Outlook Therapeutics is trading 9.9% down today at $0.94 as traders lock in profits following a sharp FDA approval-driven rally in its wet AMD program.
- The stock experienced a significant jump during the July 27 after-hours session on regulatory momentum, making today's decline a technical pullback rather than a reaction to new negative news.
- The move comes despite a broader uptrend in the biotech sector, suggesting the price action is localized to consolidation after recent gains.